hla part i: for the clinician - canadian society of transplantation · 2017-10-02 · schematic of...
TRANSCRIPT
![Page 1: HLA Part I: for the Clinician - Canadian Society of Transplantation · 2017-10-02 · Schematic of the classical complement pathway. Different components in the pathway (C1q, C4d,](https://reader033.vdocuments.site/reader033/viewer/2022050608/5faf36acc4d3e310b653a7eb/html5/thumbnails/1.jpg)
HLA – Part I: for the Clinician
James Lan, MD, FRCPC, D(ABHI)
2017 CST-Astellas Canadian Transplant Fellows Symposium
Dr. Lan completed his nephrology training at the University of British Columbia. Hethen joined the Clinician Investigator Program to cross-train in histocompatibility andimmunogenetics under the mentorship of Dr. Elaine Reed at the University ofCalifornia, Los Angeles Immunogenetics Center. He is currently Assistant Professor atthe University of British Columbia and Staff Transplant Nephrologist at the VancouverGeneral Hospital. He also serves as a Clinical Consultant for the Human LeukocyteAntigen Immunology Laboratory in BC. His clinical and research interests include thetranslation of next-generation sequencing to solid organ and hematopoietic stem celltransplantation, and application of novel solid-phase assays to risk stratify donor-specific antibodies.
![Page 2: HLA Part I: for the Clinician - Canadian Society of Transplantation · 2017-10-02 · Schematic of the classical complement pathway. Different components in the pathway (C1q, C4d,](https://reader033.vdocuments.site/reader033/viewer/2022050608/5faf36acc4d3e310b653a7eb/html5/thumbnails/2.jpg)
James H Lan, MD, FRCP(C), D(ABHI)
Assistant Professor, University of British Columbia
Nephrology & Kidney Transplantation, Vancouver General Hospital
Transplant Immunology Consultant, BCTS
CST Fellows Symposium
September 26, 2017
HLA Part I – HLA for the Clinician
![Page 3: HLA Part I: for the Clinician - Canadian Society of Transplantation · 2017-10-02 · Schematic of the classical complement pathway. Different components in the pathway (C1q, C4d,](https://reader033.vdocuments.site/reader033/viewer/2022050608/5faf36acc4d3e310b653a7eb/html5/thumbnails/3.jpg)
3
Disclosure
• I hold an Astellas/TRFBC grant
• I will discuss off-label and investigational use of drugs
![Page 4: HLA Part I: for the Clinician - Canadian Society of Transplantation · 2017-10-02 · Schematic of the classical complement pathway. Different components in the pathway (C1q, C4d,](https://reader033.vdocuments.site/reader033/viewer/2022050608/5faf36acc4d3e310b653a7eb/html5/thumbnails/4.jpg)
4
Objectives
• HLA gene, structure, nomenclature
• Methods of antibody detection and their limitations
• Application: cPRA, virtual crossmatch
• DSA risk stratification
![Page 5: HLA Part I: for the Clinician - Canadian Society of Transplantation · 2017-10-02 · Schematic of the classical complement pathway. Different components in the pathway (C1q, C4d,](https://reader033.vdocuments.site/reader033/viewer/2022050608/5faf36acc4d3e310b653a7eb/html5/thumbnails/5.jpg)
Part I. HLA Gene, Structure, Nomenclature
![Page 6: HLA Part I: for the Clinician - Canadian Society of Transplantation · 2017-10-02 · Schematic of the classical complement pathway. Different components in the pathway (C1q, C4d,](https://reader033.vdocuments.site/reader033/viewer/2022050608/5faf36acc4d3e310b653a7eb/html5/thumbnails/6.jpg)
HLA (Human Leukocyte Antigen)
Nucleated Cell
HLA-A
HLA-A
HLA-B
HLA-B
HLA-C
HLA-C
HLA-DR
HLA-DR
HLA-DQ
HLA-DQ
HLA-DP
HLA-DP
HLA Class I HLA Class II
6
![Page 7: HLA Part I: for the Clinician - Canadian Society of Transplantation · 2017-10-02 · Schematic of the classical complement pathway. Different components in the pathway (C1q, C4d,](https://reader033.vdocuments.site/reader033/viewer/2022050608/5faf36acc4d3e310b653a7eb/html5/thumbnails/7.jpg)
HLA Structure
Expressed on all nucleated cellsExpressed on B cells, antigen-presenting
cells, activated microvascular endothelium
![Page 8: HLA Part I: for the Clinician - Canadian Society of Transplantation · 2017-10-02 · Schematic of the classical complement pathway. Different components in the pathway (C1q, C4d,](https://reader033.vdocuments.site/reader033/viewer/2022050608/5faf36acc4d3e310b653a7eb/html5/thumbnails/8.jpg)
HLA Polymorphism
![Page 9: HLA Part I: for the Clinician - Canadian Society of Transplantation · 2017-10-02 · Schematic of the classical complement pathway. Different components in the pathway (C1q, C4d,](https://reader033.vdocuments.site/reader033/viewer/2022050608/5faf36acc4d3e310b653a7eb/html5/thumbnails/9.jpg)
![Page 10: HLA Part I: for the Clinician - Canadian Society of Transplantation · 2017-10-02 · Schematic of the classical complement pathway. Different components in the pathway (C1q, C4d,](https://reader033.vdocuments.site/reader033/viewer/2022050608/5faf36acc4d3e310b653a7eb/html5/thumbnails/10.jpg)
![Page 11: HLA Part I: for the Clinician - Canadian Society of Transplantation · 2017-10-02 · Schematic of the classical complement pathway. Different components in the pathway (C1q, C4d,](https://reader033.vdocuments.site/reader033/viewer/2022050608/5faf36acc4d3e310b653a7eb/html5/thumbnails/11.jpg)
• HLA antigens can be defined under different resolutions
• Useful for determination of allele-specific DSA
• Useful for epitope analysis/matching
Resolution Example Cost
Low-Resolution(antigen)
B35 $150/locus
Intermediate Resolution
B*35:XTNJ XTNJ= 01/09/11/27/28 $150/locus
High-Resolution B*35:01 $300/locus
HLA Typing Resolution
![Page 12: HLA Part I: for the Clinician - Canadian Society of Transplantation · 2017-10-02 · Schematic of the classical complement pathway. Different components in the pathway (C1q, C4d,](https://reader033.vdocuments.site/reader033/viewer/2022050608/5faf36acc4d3e310b653a7eb/html5/thumbnails/12.jpg)
Part II. Methods of Antibody Detection
1. Complement-dependent cytotoxicity (CDC)2. Flow cytometric crossmatch3. Single-antigen bead (SAB) assay
![Page 13: HLA Part I: for the Clinician - Canadian Society of Transplantation · 2017-10-02 · Schematic of the classical complement pathway. Different components in the pathway (C1q, C4d,](https://reader033.vdocuments.site/reader033/viewer/2022050608/5faf36acc4d3e310b653a7eb/html5/thumbnails/13.jpg)
“If I have seen further, it is by standing on the shoulders of giants”
- Issac Newton, 1675
![Page 14: HLA Part I: for the Clinician - Canadian Society of Transplantation · 2017-10-02 · Schematic of the classical complement pathway. Different components in the pathway (C1q, C4d,](https://reader033.vdocuments.site/reader033/viewer/2022050608/5faf36acc4d3e310b653a7eb/html5/thumbnails/14.jpg)
Famous Twins
![Page 15: HLA Part I: for the Clinician - Canadian Society of Transplantation · 2017-10-02 · Schematic of the classical complement pathway. Different components in the pathway (C1q, C4d,](https://reader033.vdocuments.site/reader033/viewer/2022050608/5faf36acc4d3e310b653a7eb/html5/thumbnails/15.jpg)
- December 23, 1954, Brigham and Women’s Hospital
First successful human kidney transplantation
![Page 16: HLA Part I: for the Clinician - Canadian Society of Transplantation · 2017-10-02 · Schematic of the classical complement pathway. Different components in the pathway (C1q, C4d,](https://reader033.vdocuments.site/reader033/viewer/2022050608/5faf36acc4d3e310b653a7eb/html5/thumbnails/16.jpg)
- Murray, Annals of Surgery, 1976
Stagnant outcomes: Imuran + steroids
![Page 17: HLA Part I: for the Clinician - Canadian Society of Transplantation · 2017-10-02 · Schematic of the classical complement pathway. Different components in the pathway (C1q, C4d,](https://reader033.vdocuments.site/reader033/viewer/2022050608/5faf36acc4d3e310b653a7eb/html5/thumbnails/17.jpg)
How to Overcome Hyperacute Rejection
![Page 18: HLA Part I: for the Clinician - Canadian Society of Transplantation · 2017-10-02 · Schematic of the classical complement pathway. Different components in the pathway (C1q, C4d,](https://reader033.vdocuments.site/reader033/viewer/2022050608/5faf36acc4d3e310b653a7eb/html5/thumbnails/18.jpg)
CDC Crossmatch
Serum
Donor
Patient
Lymphocyte
Paul TerasakiUCLA Medical School, CA, USA
b. 1929
Cells
Live cellsDead cells
+ Complement
HLA Antibody Detection: CDC crossmatch (cell-based)
![Page 19: HLA Part I: for the Clinician - Canadian Society of Transplantation · 2017-10-02 · Schematic of the classical complement pathway. Different components in the pathway (C1q, C4d,](https://reader033.vdocuments.site/reader033/viewer/2022050608/5faf36acc4d3e310b653a7eb/html5/thumbnails/19.jpg)
* p < 0.001
CDC Positive CDC Negative
No rejection 6 187
Rejection 24 (80%) * 8 (4%)
![Page 20: HLA Part I: for the Clinician - Canadian Society of Transplantation · 2017-10-02 · Schematic of the classical complement pathway. Different components in the pathway (C1q, C4d,](https://reader033.vdocuments.site/reader033/viewer/2022050608/5faf36acc4d3e310b653a7eb/html5/thumbnails/20.jpg)
Anti-IgG-FITC
B27
A2
B27
A1
B8
A2
A1
A2
B8
Donor Cell
20
Patient Serum
HLA Antibody Detection: Flow crossmatch (cell-based)
![Page 21: HLA Part I: for the Clinician - Canadian Society of Transplantation · 2017-10-02 · Schematic of the classical complement pathway. Different components in the pathway (C1q, C4d,](https://reader033.vdocuments.site/reader033/viewer/2022050608/5faf36acc4d3e310b653a7eb/html5/thumbnails/21.jpg)
HLA Antibody
Anti-IgG-FITC
B27
A2
B27
A1
B8
A2
A1
A2
B8
Donor Cell
21
Patient Serum
HLA Antibody Detection: Flow crossmatch (cell-based)
![Page 22: HLA Part I: for the Clinician - Canadian Society of Transplantation · 2017-10-02 · Schematic of the classical complement pathway. Different components in the pathway (C1q, C4d,](https://reader033.vdocuments.site/reader033/viewer/2022050608/5faf36acc4d3e310b653a7eb/html5/thumbnails/22.jpg)
Mulley, Nephrology 16 (2011) 125–133
Interpretation of flow crossmatches
Class I Class I & II
![Page 23: HLA Part I: for the Clinician - Canadian Society of Transplantation · 2017-10-02 · Schematic of the classical complement pathway. Different components in the pathway (C1q, C4d,](https://reader033.vdocuments.site/reader033/viewer/2022050608/5faf36acc4d3e310b653a7eb/html5/thumbnails/23.jpg)
SAB
23
A1
A1
A1
A1
A1
A1
A1
HLA Antibody Detection: single-antigen beads (solid phase)
![Page 24: HLA Part I: for the Clinician - Canadian Society of Transplantation · 2017-10-02 · Schematic of the classical complement pathway. Different components in the pathway (C1q, C4d,](https://reader033.vdocuments.site/reader033/viewer/2022050608/5faf36acc4d3e310b653a7eb/html5/thumbnails/24.jpg)
24
HLA Antibody Detection: single-antigen beads (solid phase)
![Page 25: HLA Part I: for the Clinician - Canadian Society of Transplantation · 2017-10-02 · Schematic of the classical complement pathway. Different components in the pathway (C1q, C4d,](https://reader033.vdocuments.site/reader033/viewer/2022050608/5faf36acc4d3e310b653a7eb/html5/thumbnails/25.jpg)
Question: What does it mean when a patient is highly sensitized? What is cPRA?
25
![Page 26: HLA Part I: for the Clinician - Canadian Society of Transplantation · 2017-10-02 · Schematic of the classical complement pathway. Different components in the pathway (C1q, C4d,](https://reader033.vdocuments.site/reader033/viewer/2022050608/5faf36acc4d3e310b653a7eb/html5/thumbnails/26.jpg)
26
cPRA (calculated panel of reactive antibody)
• cPRA = estimates the percentage of donors
in a given population who carry unacceptable
antigens for a recipient
![Page 27: HLA Part I: for the Clinician - Canadian Society of Transplantation · 2017-10-02 · Schematic of the classical complement pathway. Different components in the pathway (C1q, C4d,](https://reader033.vdocuments.site/reader033/viewer/2022050608/5faf36acc4d3e310b653a7eb/html5/thumbnails/27.jpg)
27
![Page 28: HLA Part I: for the Clinician - Canadian Society of Transplantation · 2017-10-02 · Schematic of the classical complement pathway. Different components in the pathway (C1q, C4d,](https://reader033.vdocuments.site/reader033/viewer/2022050608/5faf36acc4d3e310b653a7eb/html5/thumbnails/28.jpg)
28
cPRA calculator
![Page 29: HLA Part I: for the Clinician - Canadian Society of Transplantation · 2017-10-02 · Schematic of the classical complement pathway. Different components in the pathway (C1q, C4d,](https://reader033.vdocuments.site/reader033/viewer/2022050608/5faf36acc4d3e310b653a7eb/html5/thumbnails/29.jpg)
29
cPRA calculator
Definition of unacceptable antigen is center-specific
cPRA value is population-specific
![Page 30: HLA Part I: for the Clinician - Canadian Society of Transplantation · 2017-10-02 · Schematic of the classical complement pathway. Different components in the pathway (C1q, C4d,](https://reader033.vdocuments.site/reader033/viewer/2022050608/5faf36acc4d3e310b653a7eb/html5/thumbnails/30.jpg)
Patient 1:
Antibody: B71
cPRA = 1/100
= 1%
B71
30
Antigen frequency matters
![Page 31: HLA Part I: for the Clinician - Canadian Society of Transplantation · 2017-10-02 · Schematic of the classical complement pathway. Different components in the pathway (C1q, C4d,](https://reader033.vdocuments.site/reader033/viewer/2022050608/5faf36acc4d3e310b653a7eb/html5/thumbnails/31.jpg)
Patient 2:
Antibody: A2
cPRA = 50/100
= 50%
A2 A2 A2 A2 A2 A2 A2 A2 A2 A2
A2 A2 A2 A2 A2 A2 A2 A2 A2 A2
A2 A2 A2 A2 A2 A2 A2 A2 A2 A2
A2 A2 A2 A2 A2 A2 A2 A2 A2 A2
A2 A2 A2 A2 A2 A2 A2 A2 A2 A2
31
Antigen frequency matters
![Page 32: HLA Part I: for the Clinician - Canadian Society of Transplantation · 2017-10-02 · Schematic of the classical complement pathway. Different components in the pathway (C1q, C4d,](https://reader033.vdocuments.site/reader033/viewer/2022050608/5faf36acc4d3e310b653a7eb/html5/thumbnails/32.jpg)
Patient 3:
cPRA = 99/100
= 99%
32
Antigen frequency matters
![Page 33: HLA Part I: for the Clinician - Canadian Society of Transplantation · 2017-10-02 · Schematic of the classical complement pathway. Different components in the pathway (C1q, C4d,](https://reader033.vdocuments.site/reader033/viewer/2022050608/5faf36acc4d3e310b653a7eb/html5/thumbnails/33.jpg)
• Mrs. MC
How can someone make so many antibodies?
![Page 34: HLA Part I: for the Clinician - Canadian Society of Transplantation · 2017-10-02 · Schematic of the classical complement pathway. Different components in the pathway (C1q, C4d,](https://reader033.vdocuments.site/reader033/viewer/2022050608/5faf36acc4d3e310b653a7eb/html5/thumbnails/34.jpg)
Antibodies recognize epitopes
![Page 35: HLA Part I: for the Clinician - Canadian Society of Transplantation · 2017-10-02 · Schematic of the classical complement pathway. Different components in the pathway (C1q, C4d,](https://reader033.vdocuments.site/reader033/viewer/2022050608/5faf36acc4d3e310b653a7eb/html5/thumbnails/35.jpg)
Antibodies form in cross-reactive group species (CREG)
![Page 36: HLA Part I: for the Clinician - Canadian Society of Transplantation · 2017-10-02 · Schematic of the classical complement pathway. Different components in the pathway (C1q, C4d,](https://reader033.vdocuments.site/reader033/viewer/2022050608/5faf36acc4d3e310b653a7eb/html5/thumbnails/36.jpg)
Example of epitope spreading
![Page 37: HLA Part I: for the Clinician - Canadian Society of Transplantation · 2017-10-02 · Schematic of the classical complement pathway. Different components in the pathway (C1q, C4d,](https://reader033.vdocuments.site/reader033/viewer/2022050608/5faf36acc4d3e310b653a7eb/html5/thumbnails/37.jpg)
Patient 3:
cPRA = 99/100
= 99%
37
Solution for highly sensitized patients
![Page 38: HLA Part I: for the Clinician - Canadian Society of Transplantation · 2017-10-02 · Schematic of the classical complement pathway. Different components in the pathway (C1q, C4d,](https://reader033.vdocuments.site/reader033/viewer/2022050608/5faf36acc4d3e310b653a7eb/html5/thumbnails/38.jpg)
Patient 3:
cPRA = 99/100
= 99%
38
Solution for highly sensitized patients
![Page 39: HLA Part I: for the Clinician - Canadian Society of Transplantation · 2017-10-02 · Schematic of the classical complement pathway. Different components in the pathway (C1q, C4d,](https://reader033.vdocuments.site/reader033/viewer/2022050608/5faf36acc4d3e310b653a7eb/html5/thumbnails/39.jpg)
39
A Solution for highly sensitized patients (HSP program)
![Page 40: HLA Part I: for the Clinician - Canadian Society of Transplantation · 2017-10-02 · Schematic of the classical complement pathway. Different components in the pathway (C1q, C4d,](https://reader033.vdocuments.site/reader033/viewer/2022050608/5faf36acc4d3e310b653a7eb/html5/thumbnails/40.jpg)
Donor Typing
A 2 26
B 58 27
C 7 1
DR 17 1
DQ 2 5
Donor: Vancouver Recipient: Toronto
Compatible
?
40
Virtual crossmatch
![Page 41: HLA Part I: for the Clinician - Canadian Society of Transplantation · 2017-10-02 · Schematic of the classical complement pathway. Different components in the pathway (C1q, C4d,](https://reader033.vdocuments.site/reader033/viewer/2022050608/5faf36acc4d3e310b653a7eb/html5/thumbnails/41.jpg)
Day 0
Antibody
Testing (SAB)Organ Offer
Day 700
Sensitizing
event
No Abs
41
Ab Testing
Flow XM
Redundant assays to prevent AMR
Limitations of virtual crossmatch:
• Assume donor typing is correct
• Assume recipient antibody profile is correct
• Assume no new sensitizing events
![Page 42: HLA Part I: for the Clinician - Canadian Society of Transplantation · 2017-10-02 · Schematic of the classical complement pathway. Different components in the pathway (C1q, C4d,](https://reader033.vdocuments.site/reader033/viewer/2022050608/5faf36acc4d3e310b653a7eb/html5/thumbnails/42.jpg)
Clinical Case:
- Recipient FE: 60 y.o. Female, cPRA = 99%
- Deceased donor offer from Ontario
- DCD Donor: 68 Male, terminal Cr 70
![Page 43: HLA Part I: for the Clinician - Canadian Society of Transplantation · 2017-10-02 · Schematic of the classical complement pathway. Different components in the pathway (C1q, C4d,](https://reader033.vdocuments.site/reader033/viewer/2022050608/5faf36acc4d3e310b653a7eb/html5/thumbnails/43.jpg)
Day 0
Antibody
TestingOrgan Offer
Day 700
No Abs
43
Ab Testing
Flow XMSTAT SAB
Redundant assays to prevent AMR
Limitations of virtual crossmatch:
• Assume donor typing is correct
• Assume recipient antibody profile is correct
• Assume no new sensitizing events
![Page 44: HLA Part I: for the Clinician - Canadian Society of Transplantation · 2017-10-02 · Schematic of the classical complement pathway. Different components in the pathway (C1q, C4d,](https://reader033.vdocuments.site/reader033/viewer/2022050608/5faf36acc4d3e310b653a7eb/html5/thumbnails/44.jpg)
44
Tambur, AJT, 2015
Additional pitfalls: prozone effect
![Page 45: HLA Part I: for the Clinician - Canadian Society of Transplantation · 2017-10-02 · Schematic of the classical complement pathway. Different components in the pathway (C1q, C4d,](https://reader033.vdocuments.site/reader033/viewer/2022050608/5faf36acc4d3e310b653a7eb/html5/thumbnails/45.jpg)
Additional pitfalls: epitope pattern on beads
How to eliminate complement
interference:
1. Serum dilution
2. EDTA
3. DTT
4. Heat
- Slide courtesy Peter Nickerson
![Page 46: HLA Part I: for the Clinician - Canadian Society of Transplantation · 2017-10-02 · Schematic of the classical complement pathway. Different components in the pathway (C1q, C4d,](https://reader033.vdocuments.site/reader033/viewer/2022050608/5faf36acc4d3e310b653a7eb/html5/thumbnails/46.jpg)
Konvalinka, JASN, 2015
Additional pitfalls: epitope pattern on beads
![Page 47: HLA Part I: for the Clinician - Canadian Society of Transplantation · 2017-10-02 · Schematic of the classical complement pathway. Different components in the pathway (C1q, C4d,](https://reader033.vdocuments.site/reader033/viewer/2022050608/5faf36acc4d3e310b653a7eb/html5/thumbnails/47.jpg)
SAB is a semi-quantitative assay
- Slide courtesy Peter Nickerson
![Page 48: HLA Part I: for the Clinician - Canadian Society of Transplantation · 2017-10-02 · Schematic of the classical complement pathway. Different components in the pathway (C1q, C4d,](https://reader033.vdocuments.site/reader033/viewer/2022050608/5faf36acc4d3e310b653a7eb/html5/thumbnails/48.jpg)
Part III. DSA Risk Stratification
![Page 49: HLA Part I: for the Clinician - Canadian Society of Transplantation · 2017-10-02 · Schematic of the classical complement pathway. Different components in the pathway (C1q, C4d,](https://reader033.vdocuments.site/reader033/viewer/2022050608/5faf36acc4d3e310b653a7eb/html5/thumbnails/49.jpg)
Amico et al, Transplantation • Volume 87, 2009
DSA increase the risk of AMR
![Page 50: HLA Part I: for the Clinician - Canadian Society of Transplantation · 2017-10-02 · Schematic of the classical complement pathway. Different components in the pathway (C1q, C4d,](https://reader033.vdocuments.site/reader033/viewer/2022050608/5faf36acc4d3e310b653a7eb/html5/thumbnails/50.jpg)
Wiebe, AJT 2012
• 10-year graft survival is significantly reduced (44% vs 93%)
De Novo DSA associate with inferior long-term outcome
![Page 51: HLA Part I: for the Clinician - Canadian Society of Transplantation · 2017-10-02 · Schematic of the classical complement pathway. Different components in the pathway (C1q, C4d,](https://reader033.vdocuments.site/reader033/viewer/2022050608/5faf36acc4d3e310b653a7eb/html5/thumbnails/51.jpg)
51
Epitope pattern
Class & Locus
Preformed vs. De Novo
Kinetics
Complement activation
DSA
Determinants of the pathogenicity of DSA
![Page 52: HLA Part I: for the Clinician - Canadian Society of Transplantation · 2017-10-02 · Schematic of the classical complement pathway. Different components in the pathway (C1q, C4d,](https://reader033.vdocuments.site/reader033/viewer/2022050608/5faf36acc4d3e310b653a7eb/html5/thumbnails/52.jpg)
DSA consideration: inferior graft survival with de novo DSA
Aubert, JASN 2017
![Page 53: HLA Part I: for the Clinician - Canadian Society of Transplantation · 2017-10-02 · Schematic of the classical complement pathway. Different components in the pathway (C1q, C4d,](https://reader033.vdocuments.site/reader033/viewer/2022050608/5faf36acc4d3e310b653a7eb/html5/thumbnails/53.jpg)
DSA consideration: de novo DSA are mainly class II
Willicombe
Transplantation 2012
DeVos
Kidney Int2012
Musat
AJT2011
Smith
AJT2011
Palmer
Transplantation2002
Population Renal Renal Liver Heart Lung
De Novo DSA
18.2%
(92/502)
18%
(62/347)
63%
(27/43)
33%
(57/173)
10%
(9/90)
DQ DSA 54.3%
(50/92)
53%
(33/62)
81%
(22/27)
72%
(41/57)
56%
(5/9)
![Page 54: HLA Part I: for the Clinician - Canadian Society of Transplantation · 2017-10-02 · Schematic of the classical complement pathway. Different components in the pathway (C1q, C4d,](https://reader033.vdocuments.site/reader033/viewer/2022050608/5faf36acc4d3e310b653a7eb/html5/thumbnails/54.jpg)
54
Epitope pattern
Class & Locus
Preformed vs. De Novo
Kinetics
Complement activation
DSA
Determinants of the pathogenicity of DSA
Titer
Subclass
Number
Avidity
Glycosylation
Antigen density
![Page 55: HLA Part I: for the Clinician - Canadian Society of Transplantation · 2017-10-02 · Schematic of the classical complement pathway. Different components in the pathway (C1q, C4d,](https://reader033.vdocuments.site/reader033/viewer/2022050608/5faf36acc4d3e310b653a7eb/html5/thumbnails/55.jpg)
Figure 1. Schematic of the classical complement pathway. Different components in the pathway (C1q, C4d, C3d) are targeted in complement dependent assays to evaluate the complement-activating potential of HLA antibodies.
Lan J, et al. Transplantation 2017 (In Print)
In vitro functional assessment of complement activation
![Page 56: HLA Part I: for the Clinician - Canadian Society of Transplantation · 2017-10-02 · Schematic of the classical complement pathway. Different components in the pathway (C1q, C4d,](https://reader033.vdocuments.site/reader033/viewer/2022050608/5faf36acc4d3e310b653a7eb/html5/thumbnails/56.jpg)
56
DSA
Clinically sigComplement
Non-complement activation
Not sig
Hypothesis
Hypothesis: using complement activation to risk-stratify DSA
![Page 57: HLA Part I: for the Clinician - Canadian Society of Transplantation · 2017-10-02 · Schematic of the classical complement pathway. Different components in the pathway (C1q, C4d,](https://reader033.vdocuments.site/reader033/viewer/2022050608/5faf36acc4d3e310b653a7eb/html5/thumbnails/57.jpg)
57
Complement binding assessment assays
C1q predictive of outcomes C1q not predictive of outcomes
Yabu et al, Transplantation 2011 Crespo et al, Transpl Immunol 2013 (Pre-Tx)
Loupy et al, NEJM, 2013 Otten et al, AJT, 2012 (Pre-Tx)
Freitas et al, Transplantation, 2013 Ginevri et al, AJT, 2012
Fichtner et al, Pediatr Nephrol 2016 Wiebe et al, AJT, 2016 (not sig in multivariate)
Bamoulid et al, Transplantation, 2016
Sicard et al, JASN, 2014 (C3d)
Comoli et al, AJT, 2016 (C3d)
Guidicelli et al, JASN, 2016 (C1q)
Lefaucheur et al, JASN, 2016 (IgG subclass)
Viglietti et al, JASN, 2016 (IgG3, C1q)
![Page 58: HLA Part I: for the Clinician - Canadian Society of Transplantation · 2017-10-02 · Schematic of the classical complement pathway. Different components in the pathway (C1q, C4d,](https://reader033.vdocuments.site/reader033/viewer/2022050608/5faf36acc4d3e310b653a7eb/html5/thumbnails/58.jpg)
58
Antibody concentration and complement activation
Sicard et al, JASN, 2014 Lan et al, submitted Yell, Transplantation, 2015
![Page 59: HLA Part I: for the Clinician - Canadian Society of Transplantation · 2017-10-02 · Schematic of the classical complement pathway. Different components in the pathway (C1q, C4d,](https://reader033.vdocuments.site/reader033/viewer/2022050608/5faf36acc4d3e310b653a7eb/html5/thumbnails/59.jpg)
59
Yell, Transplantation, 2015
Manipulation of antibody concentration affects C1q positivity
In vitro C1q positivity is related to antibody concentration
![Page 60: HLA Part I: for the Clinician - Canadian Society of Transplantation · 2017-10-02 · Schematic of the classical complement pathway. Different components in the pathway (C1q, C4d,](https://reader033.vdocuments.site/reader033/viewer/2022050608/5faf36acc4d3e310b653a7eb/html5/thumbnails/60.jpg)
60
Assembly of IgG hexamers on cell surface is required for complement activation
Slide Courtesy of Peter Nickerson
Diebolder, Science, 2014
![Page 61: HLA Part I: for the Clinician - Canadian Society of Transplantation · 2017-10-02 · Schematic of the classical complement pathway. Different components in the pathway (C1q, C4d,](https://reader033.vdocuments.site/reader033/viewer/2022050608/5faf36acc4d3e310b653a7eb/html5/thumbnails/61.jpg)
61
Prevalence of isolated weak/non-complement binding IgG subclasses
Patientcohort
Prevalence of isolated IgG2/IgG4 Ab
Lefaucheur, JASN, 2016 n=125 4%
Schaub, Transplantation, 2014 n=73 5%
Arnold, Transpl Int, 2013 n=274 1%
Lowe, Human Immunol, 2013 n=51 1%
Prevalence of isolated weak/non-c’ activating HLA DSA is rare
![Page 62: HLA Part I: for the Clinician - Canadian Society of Transplantation · 2017-10-02 · Schematic of the classical complement pathway. Different components in the pathway (C1q, C4d,](https://reader033.vdocuments.site/reader033/viewer/2022050608/5faf36acc4d3e310b653a7eb/html5/thumbnails/62.jpg)
Complement dependent assays
• Antibody concentration is the dominant determinant of complement activation
• Isolated non-complement-activating antibodies (IgG2, IgG4) are rare in the clinical
setting (1-5%)
• Non-complement-activating DSAs can also be pathogenic, although the pattern of injury
may be less severe than c’-activating